Company: RNAC
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001453687-25-000060
Chunk: 9

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 9
---
 adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002———Filed herewith32.1Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002——— Furnished herewith97Cartesian Therapeutics, Inc. Compensation Clawback Policy10-K001-37798973/7/2024101.INSInline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL Document———Filed herewith101.SCHInline XBRL Taxonomy Extension Schema Document———Filed herewith101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document———Filed herewith101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document———Filed herewith101.LABInline XBRL Taxonomy Extension Label Linkbase Document———Filed herewith101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document———Filed herewith104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)———Filed herewith# Indicates management contract or compensatory plan.

74

* Certain annexes, schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request.† Certain confidential information contained in this exhibit, marked by brackets and asterisks, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because the information (i) is not material and (ii) is the type of information that the Company both customarily and actually treats as private and confidential.

Item 16.  Form 10-K Summary

None.

75

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 CARTESIAN THERAPEUTICS, INC.  Date: March 13, 2025By:/s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934,